Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - PROLOR Biotech, Inc. | v346893_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2013
PROLOR BIOTECH, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 001-34676 | 20-0854033 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
7 Golda Meir Street
Weizmann Science Park
Nes-Ziona, Israel 74140
(Address of principal executive offices) (Zip Code)
(866) 644-7811
Registrant’s telephone number, including area code
Not applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| x | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On June 4, 2013, PROLOR Biotech, Inc., a Nevada corporation (the “Company”), issued a press release announcing the termination of the “go-shop” period under the Agreement and Plan of Merger, dated as of April 23, 2013, by and among the Company, OPKO Health, Inc., a Delaware corporation, and POM Acquisition, Inc., a Nevada corporation and a direct wholly owned subsidiary of OPKO Health, Inc.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 8.01 by reference.
Item 9.01 Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 99.1 | Press Release, dated June 4, 2013 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PROLOR BIOTECH, INC. | ||
| Dated: June 4, 2013 | By: | /s/ Shai Novik |
| Name: Shai Novik | ||
| Title: President | ||
EXHIBIT INDEX
| Exhibit No. | Description |
| 99.1 | Press Release, dated June 4, 2013 |